Drug Profile
Research programme: obesity therapy - Kadmus Pharmaceuticals
Alternative Names: KDS-5000; Obesity therapy research programme - Kadmus PharmaceuticalsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Kadmus Pharmaceuticals
- Class
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in USA
- 13 Feb 2004 Preclinical trials in Obesity in USA (unspecified route)